10-Q/A

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to

Commission File Number 1-8036

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	23-1210010
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)
101 Gordon Drive, PO Box 645, Lionville, PA	19341-0645
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  þ No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  þ No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	þ		Accelerated filer	o
Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act).  Yes  o No  þ

As of July 31, 2011, there were 33,672,936 shares of the Registrant’s common stock outstanding.

EXPLANATORY NOTE

The purpose of this Amendment No. 1 to our Quarterly Report on Form 10-Q for the period ended June 30, 2011 (“Form 10-Q”), as filed with the Securities and Exchange Commission (“SEC”) on August 5, 2011, is to furnish Exhibit 101 – Interactive Data File (“XBRL Exhibit”). The XBRL Exhibit was not accepted by the SEC on August 5, 2011 due to a document type mismatch which prevented the XBRL Exhibit’s submission.

No other changes have been made to the Form 10-Q other than the furnishing of the exhibit described above. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, and does not reflect subsequent events occurring after the original filing date of the Form 10-Q or modify or update in any way disclosures made in the Form 10-Q.

ITEM 6.  EXHIBITS

See Index to Exhibits on page F-1 of this Report.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

(Registrant)

By: /s/ William J. Federici

William J. Federici

Vice President and Chief Financial Officer

August 8, 2011

3

EXHIBIT INDEX

Exhibit Number	Description
3.1*	Our Amended and Restated Articles of Incorporation effective December 17, 2007 are incorporated by reference from our Form 8-K dated December 17, 2007.
3.2*	Our Bylaws, as amended through October 14, 2008 are incorporated by reference from our Form 8-K dated October 20, 2008.
4.1*	Form of stock certificate for common stock is incorporated by reference from our annual report on Form 10-K dated May 6, 1999.
4.2*	Article 5, 6, 8(c) and 9 of our Amended and Restated Articles of Incorporation are incorporated by reference from our Form 8-K dated December 17, 2007.
4.3*	Article I and V of our Bylaws, as amended through October 14, 2008 are incorporated by reference from our Form 8-K dated October 20, 2008.
4.4*	Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted. (1)
10.1*	Credit Agreement, dated June 3, 2011, by and among West Pharmaceutical Services, Inc., our direct and indirect subsidiaries from time to time parties thereto, the several banks and other financial institutions from time to time parties thereto and PNC Bank, National Association, as administrative agent for the Lenders incorporated by reference from our Form 8-K filed on June 9, 2011.
10.2*	Security Agreement, dated June 3, 2011, by and among West Pharmaceutical Services, Inc., our subsidiaries listed on the signature pages thereto and PNC Bank, National Association, as administrative agent incorporated by reference from our Form 8-K filed on June 9, 2011.
10.3*	Global Supply Agreement between West Pharmaceutical Services, Inc. and ExxonMobil Chemical Company incorporated by reference from our Form 8-K filed on July 1, 2011.
31.1*	Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document

 

(1)    We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

*    These exhibits were previously included or incorporated by reference in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, filed on August 5, 2011.

**  Furnished with this Form 10-Q/A.

F - 1

XML



CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Millions	Jun. 30, 2011	Dec. 31, 2010
Current assets:
Cash, including cash equivalents	$ 110.4	$ 110.2
Accounts receivable, net	165.7	126.4
Inventories	161.2	147.0
Deferred income taxes	11.5	10.5
Other current assets	61.6	42.5
Total current assets	510.4	436.6
Property, plant and equipment	1,143.9	1,077.2
Less accumulated depreciation and amortization	562.4	522.4
Property, plant and equipment, net	581.5	554.8
Investments in affiliated companies	51.2	48.2
Goodwill	116.1	112.5
Deferred income taxes	71.9	64.5
Intangible assets, net	54.2	55.1
Other noncurrent assets	30.0	22.6
Total Assets	1,415.3	1,294.3
Current liabilities:
Notes payable and other current debt	6.3	0.3
Accounts payable	73.4	63.2
Pension and other postretirement benefits	2.2	2.1
Accrued salaries, wages and benefits	48.2	48.3
Income taxes payable	6.1	5.0
Taxes other than income	13.3	10.0
Other current liabilities	43.2	40.8
Total current liabilities	192.7	169.7
Long-term debt	367.2	358.1
Deferred income taxes	21.1	20.0
Pension and other postretirement benefits	92.0	87.2
Other long-term liabilities	46.3	33.6
Total Liabilities	719.3	668.6
Commitments and contingencies (Note 13)
Total Equity	696.0	625.7
Total Liabilities and Equity	$ 1,415.3	$ 1,294.3

XML



CONDENSED CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED) (USD $) In Millions	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Treasury Stock [Member]	Retained earnings [Member]	Accumulated other comprehensive (loss) income [Member]
Balance, Beginning at Dec. 31, 2010	$ 625.7	$ 8.6	$ 77.3	$ (41.5)	$ 612.6	$ (31.3)
Balance, Beginning (in shares) at Dec. 31, 2010		34.3		(1.0)
Net income	39.7				39.7
Stock-based compensation	5.4		5.4
Shares issued under stock plans	6.0		(11.2)	17.2
Shares issued under stock plans (in shares)				0.4
Shares repurchased for employee tax withholdings	(3.5)			(3.5)
Shares repurchased for employee tax withholdings (in shares)				(0.1)
Excess tax benefit from employee stock plans	3.1		3.1
Dividends declared	(11.1)				(11.1)
Other comprehensive income, net of tax	30.7					30.7
Balance, Ending at Jun. 30, 2011	$ 696.0	$ 8.6	$ 74.6	$ (27.8)	$ 641.2	$ (0.6)
Balance, Ending (in shares) at Jun. 30, 2011		34.3		(0.7)

XML



Inventories (Tables)

6 Months Ended

Jun. 30, 2011

Inventory Disclosure [Abstract]

Inventories

Note 6:  Inventories

Inventories are valued at the lower of standard cost (which approximates actual cost on a first-in-first-out basis) or market. Inventory balances were as follows:

	June 30,		December 31,
($ in millions)	2011		2010
Finished goods	$	71.9	$	65.1
Work in process		23.6		21.4
Raw materials		65.7		60.5
	$	161.2	$	147.0

XML



Document And Entity Information (USD $)	6 Months Ended
	Jun. 30, 2011	Jul. 31, 2011	Jun. 30, 2010
Entity Registrant Name	WEST PHARMACEUTICAL SERVICES INC
Entity Central Index Key	0000105770
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 1,213,616,750
Entity Common Stock, Shares Outstanding		33,672,936
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011

XML



Benefit Plans (Tables)

6 Months Ended

Jun. 30, 2011

Benefit Plans [Abstract]

Components of net periodic benefit cost

The components of net periodic benefit cost for the three months ended June 30 were as follows ($ in millions):

	Pension benefits						Other retirement benefits				Total
	2011			2010			2011		2010		2011			2010
Service cost	$	2.4		$	2.2		$	0.3	$	0.3	$	2.7		$	2.5
Interest cost		4.4			3.8			0.2		0.2		4.6			4.0
Expected return on assets		(4.5	)		(3.5	)		-		-		(4.5	)		(3.5	)
Amortization of prior service credit		(0.4	)		(0.3	)		-		-		(0.4	)		(0.3	)
Recognized actuarial losses		1.4			1.3			-		-		1.4			1.3
Net periodic benefit cost	$	3.3		$	3.5		$	0.5	$	0.5	$	3.8		$	4.0

	Pension benefits				Other retirement benefits				Total
	2011		2010		2011		2010		2011		2010
U.S. plans	$	2.7	$	3.1	$	0.5	$	0.5	$	3.2	$	3.6
International plans		0.6		0.4		-		-		0.6		0.4
Net periodic benefit cost	$	3.3	$	3.5	$	0.5	$	0.5	$	3.8	$	4.0

The components of net periodic benefit cost for the six months ended June 30 were as follows ($ in millions):

	Pension benefits						Other retirement benefits				Total
	2011			2010			2011		2010		2011			2010
Service cost	$	4.8		$	4.5		$	0.6	$	0.5	$	5.4		$	5.0
Interest cost		7.9			7.6			0.5		0.5		8.4			8.1
Expected return on assets		(7.9	)		(7.0	)		-		-		(7.9	)		(7.0	)
Amortization of transition obligation		0.1			-			-		-		0.1			-
Amortization of prior service credit		(0.8	)		(0.6	)		-		-		(0.8	)		(0.6	)
Recognized actuarial losses		2.8			2.6			-		-		2.8			2.6
Net periodic benefit cost	$	6.9		$	7.1		$	1.1	$	1.0	$	8.0		$	8.1

	Pension benefits				Other retirement benefits				Total
	2011		2010		2011		2010		2011		2010
U.S. plans	$	5.4	$	6.2	$	1.1	$	1.0	$	6.5	$	7.2
International plans		1.5		0.9		-		-		1.5		0.9
Net periodic benefit cost	$	6.9	$	7.1	$	1.1	$	1.0	$	8.0	$	8.1

XML



Revolving Credit Facility

6 Months Ended

Jun. 30, 2011

Revolving Credit Facility [Abstract]

Revolving Credit Facility

Note 7:  Revolving Credit Facility

In June 2011, we entered into a credit agreement governing our new $50.0 million revolving credit facility. The proceeds of the loans will be used to finance the construction and acquisition of our new corporate office and research facility. We currently expect to acquire the new facility during the first quarter of 2013. On the date of acquisition, the revolving loan balance will be converted to a five-year term loan. Borrowings under the loans will bear interest at a variable rate equal to one-month LIBOR plus a margin of 1.50 percentage points. The credit agreement requires us to maintain a total leverage ratio no greater than 3.50 to 1.00 and an interest coverage ratio greater than or equal to 2.50 to 1.00.

In connection with the new credit agreement, we incurred debt issuance costs of $0.3 million which are recorded in other noncurrent assets and are being amortized as additional interest expense over the term of the credit facility. As of June 30, 2011, we had no balance outstanding under this new credit facility.

XML



Segment Information (Tables)

6 Months Ended

Jun. 30, 2011

Segment Information [Abstract]

Segment Information

The following table presents information about our reportable segments, reconciled to consolidated totals:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
($ in millions)	2011			2010			2011			2010
Net sales:
Packaging Systems	$	222.2		$	200.9		$	438.0		$	399.8
Delivery Systems		86.4			82.0			166.9			158.9
Intersegment sales		(0.7	)		(1.1	)		(1.6	)		(2.2	)
Total net sales	$	307.9		$	281.8		$	603.3		$	556.5

Operating profit:
Packaging Systems	$	38.1		$	37.6		$	80.1		$	77.4
Delivery Systems		2.4			3.6			4.2			4.8
Corporate		(10.0	)		(10.3	)		(23.2	)		(21.8	)
Other unallocated items		(2.7	)		(0.4	)		(4.6	)		(1.0	)
Total operating profit	$	27.8		$	30.5		$	56.5		$	59.4
Interest expense		4.6			3.9			9.3			7.9
Interest income		(0.3	)		(0.1	)		(0.5	)		(0.2	)
Income before income taxes	$	23.5		$	26.7		$	47.7		$	51.7

XML



Segment Information (Details) (USD $) In Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Reportable Segment Information, Reconciled to Consolidated [Line Items]
Net sales	$ 307.9	$ 281.8	$ 603.3	$ 556.5
Total operating profit	27.8	30.5	56.5	59.4
Interest expense	4.6	3.9	9.3	7.9
Interest income	(0.3)	(0.1)	(0.5)	(0.2)
Income before income taxes	23.5	26.7	47.7	51.7
Separation costs, former President and COO	2.1
Packaging Systems [Member]
Reportable Segment Information, Reconciled to Consolidated [Line Items]
Net sales	222.2	200.9	438.0	399.8
Total operating profit	38.1	37.6	80.1	77.4
Delivery Systems [Member]
Reportable Segment Information, Reconciled to Consolidated [Line Items]
Net sales	86.4	82.0	166.9	158.9
Total operating profit	2.4	3.6	4.2	4.8
Intersegment [Member]
Reportable Segment Information, Reconciled to Consolidated [Line Items]
Net sales	(0.7)	(1.1)	(1.6)	(2.2)
Corporate [Member]
Reportable Segment Information, Reconciled to Consolidated [Line Items]
Total operating profit	(10.0)	(10.3)	(23.2)	(21.8)
Other Unallocated Items [Member]
Reportable Segment Information, Reconciled to Consolidated [Line Items]
Total operating profit	$ (2.7)	$ (0.4)	$ (4.6)	$ (1.0)

XML



Comprehensive Income (Tables)

6 Months Ended

Jun. 30, 2011

Comprehensive Income [Abstract]

Comprehensive Income

Comprehensive income (loss) was as follows:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
($ in millions)	2011			2010			2011			2010
Net income	$	20.1		$	21.7		$	39.7		$	41.6
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments		10.2			(28.0	)		31.5			(46.6	)
Defined benefit pension and other postretirement plans		0.6			0.8			0.5			2.0
Unrealized gains (losses) on derivatives:
Unrealized gains arising during the period		0.1			0.4			0.1			0.9
Losses included in net income		(0.6	)		(0.8	)		(1.4	)		(1.6	)
Net unrealized losses on derivatives		(0.5	)		(0.4	)		(1.3	)		(0.7	)
Other comprehensive income (loss), net of tax		10.3			(27.6	)		30.7			(45.3	)
Comprehensive income (loss)	$	30.4		$	(5.9	)	$	70.4		$	(3.7	)

XML



Segment Information

6 Months Ended

Jun. 30, 2011

Segment Information [Abstract]

Segment Information

Note 12:  Segment Information

Our operations are comprised of two reportable segments: Pharmaceutical Packaging Systems (“Packaging Systems”) and Pharmaceutical Delivery Systems (“Delivery Systems”). Packaging Systems consists of our core pharmaceutical packaging products for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, intravenous and blood collection systems, as well as laboratory and other services. Delivery Systems develops, manufactures and sells safety and administration systems, multi-component systems for drug administration, and a variety of custom contract-manufacturing solutions targeted to the healthcare and consumer-products industries. In addition, Delivery Systems is responsible for the continued development and commercialization of our line of proprietary, multi-component systems for injectable drug administration and other healthcare applications.

Segment operating profit excludes general corporate costs, including stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment and certain pension and other retirement benefit costs. Also excluded are items that management considers not representative of ongoing operations, such as restructuring and related charges, certain asset impairments and other specifically identified gains and losses.

The following table presents information about our reportable segments, reconciled to consolidated totals:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
($ in millions)	2011			2010			2011			2010
Net sales:
Packaging Systems	$	222.2		$	200.9		$	438.0		$	399.8
Delivery Systems		86.4			82.0			166.9			158.9
Intersegment sales		(0.7	)		(1.1	)		(1.6	)		(2.2	)
Total net sales	$	307.9		$	281.8		$	603.3		$	556.5

Operating profit:
Packaging Systems	$	38.1		$	37.6		$	80.1		$	77.4
Delivery Systems		2.4			3.6			4.2			4.8
Corporate		(10.0	)		(10.3	)		(23.2	)		(21.8	)
Other unallocated items		(2.7	)		(0.4	)		(4.6	)		(1.0	)
Total operating profit	$	27.8		$	30.5		$	56.5		$	59.4
Interest expense		4.6			3.9			9.3			7.9
Interest income		(0.3	)		(0.1	)		(0.5	)		(0.2	)
Income before income taxes	$	23.5		$	26.7		$	47.7		$	51.7

During the second quarter of 2011, we incurred $2.1 million in separation costs related to the retirement of our former President and Chief Operating Officer. These costs are included within other unallocated items and consist primarily of stock-based compensation expense. The respective equity compensation arrangements were amended to allow certain of his awards to continue to vest over the original vesting period instead of being forfeited upon separation, resulting in a revaluation of the awards and acceleration of expense.

Also included within other unallocated items are restructuring and related costs, as well as other specifically identified gains and losses, which are discussed further in Note 2, Restructuring and Other Items.

XML



Income Taxes

6 Months Ended

Jun. 30, 2011

Income Taxes [Abstract]

Income Taxes

Note 3:  Income Taxes

The tax provision for interim periods is determined using the estimated annual effective tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. For the three and six months ended June 30, 2011, our effective tax rate was 22.5% and 23.7%, respectively, compared with 24.6% for both periods in 2010. Discrete tax items did not have a significant impact on our effective tax rate for the three and six month periods ended June 30, 2011. In the second quarter of 2010, we recognized a $0.5 million discrete tax charge.

It is reasonably possible that, due to the expiration of statutes and the closing of audits during the next twelve months, the total amount of unrecognized tax benefits may be reduced further by approximately $0.8 million, resulting in a favorable impact on the effective tax rate. During each of the six month periods ended June 30, 2011 and 2010, we recognized $0.1 million in tax-related interest expense. The balance of accrued interest related to uncertain tax positions was $0.5 million and $0.4 million at June 30, 2011 and December 31, 2010, respectively.

Because we are a global organization, we and our subsidiaries file income tax returns in the U.S. Federal jurisdiction and various state and foreign jurisdictions. We are subject to examination in the U.S. Federal tax jurisdiction for tax years 2007 through 2010. We are also open for examination in various state and foreign jurisdictions for tax years 2005 through 2010.

XML



Comprehensive Income (Details) (USD $) In Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Comprehensive Income [Abstract]
Net income	$ 20.1	$ 21.7	$ 39.7	$ 41.6
Other comprehensive income (loss), net of tax: [Abstract]
Foreign currency translation adjustments	10.2	(28.0)	31.5	(46.6)
Defined benefit pension and other postretirement plans	0.6	0.8	0.5	2.0
Unrealized gains (losses) on derivatives: [Abstract]
Unrealized gains arising during the period	0.1	0.4	0.1	0.9
Losses included in net income	(0.6)	(0.8)	(1.4)	(1.6)
Net unrealized losses on derivatives	(0.5)	(0.4)	(1.3)	(0.7)
Other comprehensive income (loss), net of tax	10.3	(27.6)	30.7	(45.3)
Comprehensive income (loss)	$ 30.4	$ (5.9)	$ 70.4	$ (3.7)

XML



Comprehensive Income

6 Months Ended

Jun. 30, 2011

Comprehensive Income [Abstract]

Comprehensive Income

Note 9:  Comprehensive Income (Loss)

Comprehensive income (loss) was as follows:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
($ in millions)	2011			2010			2011			2010
Net income	$	20.1		$	21.7		$	39.7		$	41.6
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments		10.2			(28.0	)		31.5			(46.6	)
Defined benefit pension and other postretirement plans		0.6			0.8			0.5			2.0
Unrealized gains (losses) on derivatives:
Unrealized gains arising during the period		0.1			0.4			0.1			0.9
Losses included in net income		(0.6	)		(0.8	)		(1.4	)		(1.6	)
Net unrealized losses on derivatives		(0.5	)		(0.4	)		(1.3	)		(0.7	)
Other comprehensive income (loss), net of tax		10.3			(27.6	)		30.7			(45.3	)
Comprehensive income (loss)	$	30.4		$	(5.9	)	$	70.4		$	(3.7	)

XML



New Accounting Standards

6 Months Ended

Jun. 30, 2011

New Accounting Standards [Abstract]

New Accounting Standards

Note 14:  New Accounting Standards

Recently Adopted Standards

In December 2010, the FASB issued amended guidance for business combinations. The update addresses diversity in the interpretation of the pro forma revenue and earnings disclosure requirements for business combinations, and defines the periods for which pro forma information should be presented. This guidance was effective for us as of January 1, 2011 and will be applied prospectively to business combinations entered into on or after that date.

In September 2009, the FASB issued revised guidance for multiple-deliverable revenue arrangements. The guidance requires companies to allocate revenue in these types of arrangements based on an element’s estimated selling price if vendor-specific or other third-party evidence is not available. This guidance also expands required disclosures. We adopted this guidance as of January 1, 2011, on a prospective basis. The adoption did not have a material impact on our financial statements.

Standards Issued Not Yet Adopted

In June 2011, the FASB issued guidance which requires an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income, or in two separate but consecutive statements. This guidance eliminates the option to report components of other comprehensive income as part of the statement of equity. This guidance is effective for reporting periods beginning on or after December 15, 2011.  Management believes the adoption will not have a material impact on our financial statements.

In May 2011, the FASB issued guidance to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. It also changes certain fair value measurement principles and expands the disclosures for fair value measurements that are estimated using significant unobservable inputs. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2011. Management believes the adoption will not have a material impact on our financial statements.

XML



Stock-Based Compensation

6 Months Ended

Jun. 30, 2011

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Note 10:  Stock-Based Compensation

In the first quarter of 2011, we granted 471,468 stock options at a weighted average exercise price of $40.85 per share based on the grant-date fair value of our stock to key employees under the 2007 Omnibus Incentive Compensation Plan (the “2007 Plan”). Stock options granted to employees vest in equal annual increments over four years of continuous service. All awards expire ten years from the date of grant. The weighted average grant date fair value of options granted was $8.76 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 2.16%; expected life of 5.5 years based on prior experience; stock volatility of 24.3% based on historical data; and a dividend yield of 1.7%. Stock option expense is recognized over the vesting period, net of forfeitures.

In addition, during the first quarter of 2011, we granted 101,099 performance-vesting share (“PVS”) awards at a grant-date fair value of $40.85 per share to key employees under the 2007 Plan. Each PVS award entitles the holder to one share of our common stock if the annual growth rate of revenue and return on invested capital targets are achieved over a three-year performance period. The actual payout may vary from 0% to 200% of an employee’s targeted award. The fair value of PVS awards was based on the market price of our stock at the grant date and is recognized as an expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

On May 3, 2011, the 2011 Omnibus Incentive Compensation Plan (the “2011 Plan”) was approved by our shareholders.  All remaining shares available for issuance under the 2007 Plan were extinguished upon adoption of the 2011 Plan.  Awards granted under previous plans remain outstanding until expiration or settlement.  The 2011 Plan provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted.  Vesting requirements vary by award.

At inception, there were 4,800,000 shares of common stock available for issuance under the 2011 Plan.  Stock options and stock appreciation rights reduce the number of shares available by one share for each award granted.  All other awards that will be distributed in stock under the 2011 Plan will reduce the total number of shares available for grant by an amount equal to 2.35 times the number of shares awarded.  If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2011 Plan. At June 30, 2011, there were 4,735,429 shares remaining in the 2011 Plan.

XML



Inventories (Details) (USD $) In Millions	Jun. 30, 2011	Dec. 31, 2010
Inventories, net [Abstract]
Finished goods	$ 71.9	$ 65.1
Work in process	23.6	21.4
Raw materials	65.7	60.5
Total inventories	$ 161.2	$ 147.0

XML



Net Income Per Share

6 Months Ended

Jun. 30, 2011

Net income per share

Net Income Per Share

Note 8:  Net Income Per Share

The following table reconciles net income and shares used in the calculation of basic net income per share to those used for diluted net income per share:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
($ in millions)	2011		2010		2011		2010
Net income, as reported, for basic net income per share	$	20.1	$	21.7	$	39.7	$	41.6
Plus: interest expense on convertible debt, net of tax		1.1		1.1		2.1		2.1
Net income for diluted net income per share	$	21.2	$	22.8	$	41.8	$	43.7

Weighted average common shares outstanding	33.6	33.3	33.5	33.2
Assumed stock options exercised and awards vested, based on the treasury stock method	0.5	0.5	0.5	0.5
Assumed conversion of convertible debt, based on the if-converted method	2.9	2.9	2.9	2.9
Weighted average shares assuming dilution	37.0	36.7	36.9	36.6

Options to purchase 1.0 million and 1.3 million shares of our common stock for the three months ended June 30, 2011 and 2010, respectively, were not included in the computation of diluted net income per share because their impact would be antidilutive. There were 1.2 million and 1.0 million antidilutive options outstanding during the six month periods ended June 30, 2011 and 2010, respectively.

XML



Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2011

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 1:  Summary of Significant Accounting Policies

Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial reporting and Securities and Exchange Commission ("SEC") regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and six month periods ended June 30, 2011 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. (which may be referred to as "West", "the Company", "we", "us" or "our"), appearing in our Annual Report on Form 10-K for the year ended December 31, 2010 ("2010 Annual Report"). The results of operations for any interim period are not necessarily indicative of results for the full year.

XML



Derivative Financial Instruments

6 Months Ended

Jun. 30, 2011

Derivative Financial Instruments [Abstract]

Derivative Financial Instruments

Note 4:  Derivative Financial Instruments

Our ongoing business operations expose us to various risks such as fluctuating interest rates, foreign exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments such as interest rate swaps, options and foreign exchange contracts for periods consistent with and for notional amounts equal to or less than the related underlying exposures. We do not purchase or hold any derivative financial instruments for speculation or trading purposes. All derivatives are recorded on the balance sheet at fair value.

Interest Rate Risk

On February 25, 2011, we exercised an option to purchase our new corporate office and research facility. Refer to Note 13, Commitments and Contingent Liabilities, for additional details. In conjunction with this, we anticipate that during the first quarter of 2013, we will borrow $43.0 million pursuant to a five-year term loan with a variable interest rate. In anticipation of this debt, we entered into a forward-start interest rate swap with the same notional amount in order to hedge the variability in cash flows due to changes in the applicable interest rate over the five-year period beginning January 2013. Under this swap, we will receive variable interest rate payments based on one-month London Interbank Offering Rates (“LIBOR”) plus a margin in return for making monthly fixed interest payments at 5.41%. We designated the forward-start interest rate swap as a cash flow hedge.

As a result of our normal borrowing activities, we have entered into long-term debt obligations with both fixed and variable interest rates. As of June 30, 2011, we have two interest rate swap agreements outstanding. Both swap agreements are designated as cash flow hedges to protect against volatility in the interest rates payable on our $50.0 million note maturing July 28, 2012 (“Series A Note”) and our $25.0 million note maturing July 28, 2015 (“Series B Note”). Under both of these swaps, we will receive variable interest rate payments based on three-month LIBOR in return for making quarterly fixed rate payments. Including the applicable margin, the interest rate swap agreements effectively fix the interest rates payable on the Series A and B notes at 5.32% and 5.51%, respectively.

Foreign Exchange Rate Risk

As described in more detail below, during 2011, we entered into several foreign currency hedge contracts that were designated as cash flow hedges of forecasted transactions denominated in foreign currencies.

We entered into a series of foreign currency contracts intended to hedge the currency risk associated with a portion of our forecasted Japanese Yen (“JPY”) denominated purchases of inventory from Daikyo Seiko Ltd. made by certain European subsidiaries. As of June 30, 2011, there were six monthly contracts outstanding at ¥95.0 million each, for an aggregate notional amount of ¥570.0 million (approximately $7.0 million).

We have also entered into a series of foreign currency contracts to hedge the currency risk associated with a portion of our forecasted U.S. dollar (“USD”) denominated inventory purchases by certain European subsidiaries. As of June 30, 2011, there were six monthly contracts outstanding at $0.8 million each, for an aggregate notional amount of $4.8 million.

In addition, we entered into a series of foreign currency contracts to hedge the currency risk associated with a portion of our forecasted Euro-denominated sales of finished goods by one of our USD functional-currency subsidiaries. As of June 30, 2011, there were six monthly contracts outstanding at $1.2 million each, for an aggregate notional amount of $7.2 million.

As of June 30, 2011 and December 31, 2010, a portion of our long-term debt consisted of borrowings denominated in currencies other than the U.S. dollar. We designated our €81.5 million Euro-denominated notes as a hedge of our net investment in certain European subsidiaries. A cumulative foreign currency translation loss of $17.2 million pre-tax ($10.6 million after tax) on this debt was recorded within accumulated other comprehensive loss as of June 30, 2011. We have also designated our 1.0 billion Yen-denominated note payable as a hedge of our net investment in a Japanese affiliate. At June 30, 2011, there was a cumulative foreign currency translation loss on this Yen-denominated debt of $1.5 million pre-tax ($0.9 million after tax) which was also included within accumulated other comprehensive loss.

Commodity Price Risk

Many of our Packaging Systems products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. We entered into the following economic hedges that did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

In January 2011, we purchased a series of call options for a total of 77,900 barrels of crude oil, intended to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases during the months of May through November 2011. With these option contracts, we may benefit from a decline in crude oil prices, as there is no downward exposure other than the $0.5 million premium that we paid to purchase the contracts.

During the three and six month periods ended June 30, 2011, a loss of $0.2 million and a gain of $0.7 million, respectively, was recorded in cost of goods and services sold related to these outstanding call options. During the three and six month periods ended June 30, 2010, a loss of $0.2 million and $0.3 million, respectively, related to crude-oil options was recorded in cost of goods and services sold.

Effects of Derivative Instruments on Financial Position and Results of Operations

Refer to Note 5, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of June 30, 2011 and December 31, 2010.

The following tables summarize the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings:

	Amount of Gain (Loss) Recognized in OCI for Three Months Ended June 30,					Amount of Gain (Loss) Reclassified from Accumulated OCI into Income for Three Months Ended June 30,						Location of Gain (Loss) Reclassified from Accumulated OCI into Income
($ in millions)	2011			2010		2011			2010
Cash Flow Hedges:
Foreign currency hedge contracts	$	(0.2	)	$	-	$	0.2		$	-		Net sales
Foreign currency hedge contracts		0.2			0.1		-			-		Cost of goods and services sold
Interest rate swap contracts		0.1			0.3		(0.8	)		(0.8	)	Interest expense
Total	$	0.1		$	0.4	$	(0.6	)	$	(0.8	)
Net Investment Hedges:
Foreign currency-denominated debt	$	(1.6	)	$	9.3	$	-		$	-		Foreign exchange (gains) losses and other
Total	$	(1.6	)	$	9.3	$	-		$	-

	Amount of Gain (Loss) Recognized in OCI for Six Months Ended June 30,					Amount of Gain (Loss) Reclassified from Accumulated OCI into Income for Six Months Ended June 30,						Location of Gain (Loss) Reclassified from Accumulated OCI into Income
($ in millions)	2011			2010		2011			2010
Cash Flow Hedges:
Foreign currency hedge contracts	$	(0.5	)	$	-	$	0.2		$	-		Net sales
Foreign currency hedge contracts		(0.6	)		0.1		-			-		Cost of goods and services sold
Interest rate swap contracts		1.2			0.8		(1.6	)		(1.6	)	Interest expense
Total	$	0.1		$	0.9	$	(1.4	)	$	(1.6	)
Net Investment Hedges:
Foreign currency-denominated debt	$	(5.8	)	$	16.6	$	-		$	-		Foreign exchange (gains) losses and other
Total	$	(5.8	)	$	16.6	$	-		$	-

For the three and six month periods ended June 30, 2011 and 2010, there was no ineffectiveness related to our cash flow and net investment hedges.

XML



Fair Value of Financial Instruments (Details) (USD $) In Millions	6 Months Ended
	Jun. 30, 2011	Dec. 31, 2010
Assets: [Abstract]
Short-term investments	$ 15.4	$ 0.6
Deferred compensation assets	3.6	3.6
Commodity contracts	1.1
Total assets at fair value	20.1	4.2
Liabilities: [Abstract]
Contingent consideration liability	1.7	2.3
Deferred compensation liabilities	5.3	5.4
Foreign currency contracts	1.2
Interest rate swap contracts	6.8	6.1
Total liabilities at fair value	15.0	13.8
Level 3 Fair Value Measurements [Roll Forward]
Beginning Balance	2.3
Increase in fair value recorded in earnings	0.1
Reduction in fair value recorded in earnings	(0.8)
Changes in foreign currency exchange rates	0.1
Ending Balance	1.7
Other Financial Instruments [Abstract]
Fair value of long-term debt	361.4	344.2
Carrying amount of long-term debt	367.2	358.1
Level 1 [Member]
Assets: [Abstract]
Short-term investments	15.4	0.6
Deferred compensation assets	3.6	3.6
Total assets at fair value	19.0	4.2
Liabilities: [Abstract]
Deferred compensation liabilities	5.3	5.4
Total liabilities at fair value	5.3	5.4
Level 2 [Member]
Assets: [Abstract]
Commodity contracts	1.1
Total assets at fair value	1.1
Liabilities: [Abstract]
Foreign currency contracts	1.2
Interest rate swap contracts	6.8	6.1
Total liabilities at fair value	8.0	6.1
Level 3 [Member]
Liabilities: [Abstract]
Contingent consideration liability	1.7	2.3
Total liabilities at fair value	$ 1.7	$ 2.3

XML



Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2011

Fair Value Measurements [Abstract]

Fair Value Measurements

Note 5:  Fair Value Measurements

We define fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

?   Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

?   Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

?   Level 3: Unobservable inputs that reflect the reporting entity's own assumptions.

The following tables present the assets and liabilities that are measured at fair value on a recurring basis in our balance sheets:

	Balance at		Basis of Fair Value Measurements
	June 30,
($ in millions)	2011		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	15.4	$	15.4	$	-	$	-
Deferred compensation assets		3.6		3.6		-		-
Commodity contracts		1.1		-		1.1		-
	$	20.1	$	19.0	$	1.1	$	-
Liabilities:
Contingent consideration	$	1.7	$	-	$	-	$	1.7
Deferred compensation liabilities		5.3		5.3		-		-
Foreign currency contracts		1.2		-		1.2		-
Interest rate swap contracts		6.8		-		6.8		-
	$	15.0	$	5.3	$	8.0	$	1.7

	Balance at		Basis of Fair Value Measurements
	December 31,
($ in millions)	2010		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	0.6	$	0.6	$	-	$	-
Deferred compensation assets		3.6		3.6		-		-
	$	4.2	$	4.2	$	-	$	-
Liabilities:
Contingent consideration	$	2.3	$	-	$	-	$	2.3
Deferred compensation liabilities		5.4		5.4		-		-
Interest rate swap contracts		6.1		-		6.1		-
	$	13.8	$	5.4	$	6.1	$	2.3

Short-term investments, which are comprised of certificates of deposit and mutual funds, are included within other current assets and are valued using a market approach based on quoted market prices in an active market. Deferred compensation assets are included within other current assets and are also valued using a market approach based on quoted market prices in an active market. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees' investment selections and is included within other long-term liabilities.

Commodity contracts are included within other current assets and are valued using an income approach. The fair value of our foreign currency contracts was included within other current liabilities and was valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. Interest rate swaps are included within other long-term liabilities and are valued using a discounted cash flow analysis based on the terms of the contract and observable market inputs (i.e. LIBOR, Eurodollar forward rates and swap spreads). Refer to Note 4, Derivative Financial Instruments, for further discussion of our derivatives.

The fair value of the contingent consideration was determined using a probability-weighted income approach at the acquisition date and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of these obligations are recorded as income or expense within restructuring and other items in our consolidated statements of income. The fair value measurement is based on significant inputs not observable in the market, which are referred to as Level 3 inputs.

The following table provides a summary of changes in our Level 3 fair value measurements:

	($ in millions)
Balance, December 31, 2010	$	2.3
Increase in fair value recorded in earnings		0.1
Reduction in fair value recorded in earnings		(0.8	)
Changes in foreign currency exchange rates		0.1
Balance, June 30, 2011	$	1.7

Refer to Note 2, Restructuring and Other Items, for further discussion of acquisition-related contingencies.

Other Financial Instruments

Cash and cash equivalents, accounts receivable and short-term debt are held at carrying amounts that approximate fair value due to their near-term maturities. Quoted market prices are used to estimate the fair value of publicly traded long-term debt. Debt that is not quoted on an exchange is valued using a discounted cash flow method based on interest rates that are currently available to us for debt issuances with similar terms and maturities. At June 30, 2011, the estimated fair value of long-term debt was $361.4 million compared to a carrying amount of $367.2 million. At December 31, 2010, the estimated fair value of long-term debt was $344.2 million and the carrying amount was $358.1 million.

XML



Restructuring and Other Items (Details) (USD $) In Millions	3 Months Ended		6 Months Ended			1 Months Ended	6 Months Ended	12 Months Ended	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011 Severance and benefits [Member]	Dec. 31, 2010 2010 Program [Member]	Jun. 30, 2011 2010 Program [Member]	Dec. 31, 2011 2010 Program [Member]	Jun. 30, 2010 2009 Program [Member]	Jun. 30, 2011 Other Costs [Member]
Restructuring and Other Items [Abstract]
Severance and post-employment benefits	$ 0.3	$ 0	$ 1.7	$ 0.4
Impairments and asset write-offs	0.4	0.3	0.7	0.4
Other restructuring charges	0.6	0.1	0.8	0.2
Total restructuring and related charges	1.3	0.4	3.2	1.0
Acquisition-related contingencies	(0.7)	0	(0.7)	0
Foreign exchange losses and other	0.4	0.8	0.2	1.5
Total restructuring and other items	1.0	1.2	2.7	2.5
Restructuring Obligation [Roll forward]
Beginning Balance			10.2		10.2					0
Charges			2.5		1.7					0.8
Cash payments			(3.1)		(2.3)					(0.8)
Foreign currency translation adjustments			(0.1)		(0.1)					0
Ending Balance	9.5		9.5		9.5					0
Expected total restructuring and related charges, low end of range							22.0
Expected total restructuring and related charges, high end of range							23.0
Expected cash expenditures, lower range							15.0
Expected cash expenditures, upper range							16.0
Expected non-cash charges							7.0
Restructuring costs incurred to date						14.5	3.2		1.0
Expected total restructuring and related charges								5.0
Reduction of eris contingent consideration liability	(0.8)
Contingent consideration liability - eris	$ 0		$ 0

XML



Revolving Credit Facility (Details) (Revolving Credit50 Million Facility [Member], USD $) In Millions, unless otherwise specified	6 Months Ended
	Jun. 30, 2011
Revolving Credit50 Million Facility [Member]
Line of Credit Facility [Line Items]
Initiation date	June 2011
Amount of revolving credit facility	$ 50.0
Credit facility conversion description	On the date of acquisition, the revolving loan balance will be converted to a five-year term loan
Variable rate basis	one-month LIBOR
Spread on variable rate (in hundredths)	1.50%
Credit agreement requirements	total leverage ratio no greater than 3.50 to 1.00 and an interest coverage ratio greater than or equal to 2.50 to 1.00
Debt issuance costs	0.3
Amount outstanding	$ 0

XML



Derivative Financial Instruments (Details) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended													1 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2011 USD ($)	Jun. 30, 2010 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2010 USD ($)	Jun. 30, 2011 Forward-Start Interest Rate Swap [Member] USD ($)	Jun. 30, 2011 Interest Rate Swap, Series A Note [Member] USD ($)	Jun. 30, 2011 Interest Rate Swap, Series B Note [Member] USD ($)	Jun. 30, 2011 Foreign Currency Hedge, Inventory Purchases, Yen [Member] USD ($)	Jun. 30, 2011 Foreign Currency Hedge, Inventory Purchases, Yen [Member] JPY (¥)	Jun. 30, 2011 Foreign Currency Hedge, Euro-Denominated Sales [Member] USD ($)	Jun. 30, 2011 Foreign Currency Hedge, Inventory Purchases, Dollars USD ($)	Jun. 30, 2011 Euro-Denominated Note [Member] USD ($)	Jun. 30, 2011 Euro-Denominated Note [Member] EUR (€)	Jun. 30, 2011 Yen-Denominated Note [Member] USD ($)	Jun. 30, 2011 Yen-Denominated Note [Member] JPY (¥)	Jan. 31, 2011 Commodity Call Options [Member] USD ($)	Jun. 30, 2011 Commodity Call Options [Member] USD ($)	Jun. 30, 2010 Commodity Call Options [Member] USD ($)	Jun. 30, 2011 Commodity Call Options [Member] USD ($)	Jun. 30, 2010 Commodity Call Options [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Net Sales [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Net Sales [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Net Sales [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Net Sales [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Cost of Goods and Services Sold [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Cost of Goods and Services Sold [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Cost of Goods and Services Sold [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Cost of Goods and Services Sold [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] Interest Rate Swap Contracts [Member] Interest Expense [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] Interest Rate Swap Contracts [Member] Interest Expense [Member] USD ($)	Jun. 30, 2011 Cash Flow Hedges [Member] Interest Rate Swap Contracts [Member] Interest Expense [Member] USD ($)	Jun. 30, 2010 Cash Flow Hedges [Member] Interest Rate Swap Contracts [Member] Interest Expense [Member] USD ($)	Jun. 30, 2011 Net Investment Hedges [Member] USD ($)	Jun. 30, 2010 Net Investment Hedges [Member] USD ($)	Jun. 30, 2011 Net Investment Hedges [Member] USD ($)	Jun. 30, 2010 Net Investment Hedges [Member] USD ($)	Jun. 30, 2011 Net Investment Hedges [Member] Foreign Currency - Denominated Debt [Member] Foreign Exchange (Gains) Losses and Other [Member] USD ($)	Jun. 30, 2010 Net Investment Hedges [Member] Foreign Currency - Denominated Debt [Member] Foreign Exchange (Gains) Losses and Other [Member] USD ($)	Jun. 30, 2011 Net Investment Hedges [Member] Foreign Currency - Denominated Debt [Member] Foreign Exchange (Gains) Losses and Other [Member] USD ($)	Jun. 30, 2010 Net Investment Hedges [Member] Foreign Currency - Denominated Debt [Member] Foreign Exchange (Gains) Losses and Other [Member] USD ($)
Derivative Financial Instruments [Line Items]
Amount of hedged item					$ 43.0	$ 50.0	$ 25.0
Fixed interest rate					5.41%	5.32%	5.51%
Variable rate basis					one-month LIBOR	three-month LIBOR	three-month LIBOR
Maximum term (in years)					Five
Maturity date of debt						Jul. 28, 2012	Jul. 28, 2015
Number of monthly contracts remaining								6	6	6	6
Notional amount									95.0	1.2	0.8
Aggregate notional amount of remaining contracts								7.0	570.0	7.2	4.8
Notional amount, nonderivative instruments													81.5		1,000.0
Cumulative foreign currency translation loss, pre-tax												17.2		1.5
Cumulative foreign currency translation loss, net of tax												10.6		0.9
Purchased call options, barrels of crude oil (in barrels)																77,900
Premium paid to purchase call options																0.5
Gain (loss) recorded in cost of goods and services sold, call options																	(0.2)	(0.2)	0.7	(0.3)
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI																					0.1	0.4	0.1	0.9	(0.2)	0	(0.5)	0	0.2	0.1	(0.6)	0.1	0.1	0.3	1.2	0.8	(1.6)	9.3	(5.8)	16.6	(1.6)	9.3	(5.8)	16.6
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income																					(0.6)	(0.8)	(1.4)	(1.6)	0.2	0	0.2	0	0	0	0	0	(0.8)	(0.8)	(1.6)	(1.6)	0	0	0	0	0	0	0	0
Ineffectiveness, cash flow hedges	0	0	0	0
Ineffectiveness, net investment hedges	$ 0	$ 0	$ 0	$ 0

XML



Commitments and Contingent Liabilities

6 Months Ended

Jun. 30, 2011

Commitments and Contingent Liabilities [Abstract]

Commitments and Contingent Liabilities

Note 13:  Commitments and Contingent Liabilities

From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business or financial position.

Except as discussed below, there have been no significant changes to the commitments and contingent liabilities that were included in our 2010 Annual Report.

The construction of our new corporate office and research facility, which will replace our existing corporate office lease, commenced in the first quarter of 2011 and is expected to take a total of two years to complete. The majority of the building will be constructed under our agreement with a real estate development company. Amounts incurred under this agreement will be accrued to property, plant and equipment and other long-term liabilities until they are paid at settlement, which is expected in the first quarter of 2013. We expect to incur total construction and development costs related to this facility of approximately $66.0 million.

XML



Inventories

6 Months Ended

Jun. 30, 2011

Inventory Disclosure [Abstract]

Inventories

Note 6:  Inventories

Inventories are valued at the lower of standard cost (which approximates actual cost on a first-in-first-out basis) or market. Inventory balances were as follows:

	June 30,		December 31,
($ in millions)	2011		2010
Finished goods	$	71.9	$	65.1
Work in process		23.6		21.4
Raw materials		65.7		60.5
	$	161.2	$	147.0

XML



Derivative Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2011

Derivative Financial Instruments [Abstract]

Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and earnings

The following tables summarize the effects of derivative instruments designated as hedges on other comprehensive income ("OCI") and earnings:

	Amount of Gain (Loss) Recognized in OCI for Three Months Ended June 30,					Amount of Gain (Loss) Reclassified from Accumulated OCI into Income for Three Months Ended June 30,						Location of Gain (Loss) Reclassified from Accumulated OCI into Income
($ in millions)	2011			2010		2011			2010
Cash Flow Hedges:
Foreign currency hedge contracts	$	(0.2	)	$	-	$	0.2		$	-		Net sales
Foreign currency hedge contracts		0.2			0.1		-			-		Cost of goods and services sold
Interest rate swap contracts		0.1			0.3		(0.8	)		(0.8	)	Interest expense
Total	$	0.1		$	0.4	$	(0.6	)	$	(0.8	)
Net Investment Hedges:
Foreign currency-denominated debt	$	(1.6	)	$	9.3	$	-		$	-		Foreign exchange (gains) losses and other
Total	$	(1.6	)	$	9.3	$	-		$	-

	Amount of Gain (Loss) Recognized in OCI for Six Months Ended June 30,					Amount of Gain (Loss) Reclassified from Accumulated OCI into Income for Six Months Ended June 30,						Location of Gain (Loss) Reclassified from Accumulated OCI into Income
($ in millions)	2011			2010		2011			2010
Cash Flow Hedges:
Foreign currency hedge contracts	$	(0.5	)	$	-	$	0.2		$	-		Net sales
Foreign currency hedge contracts		(0.6	)		0.1		-			-		Cost of goods and services sold
Interest rate swap contracts		1.2			0.8		(1.6	)		(1.6	)	Interest expense
Total	$	0.1		$	0.9	$	(1.4	)	$	(1.6	)
Net Investment Hedges:
Foreign currency-denominated debt	$	(5.8	)	$	16.6	$	-		$	-		Foreign exchange (gains) losses and other
Total	$	(5.8	)	$	16.6	$	-		$	-

XML



Commitments and Contingent Liabilities (Details) (USD $) In Millions	6 Months Ended
	Jun. 30, 2011
Commitments and Contingent Liabilities [Abstract]
Expected costs to construct new facility	$ 66.0
Expected costs for new facility, time period (in years)	Two

XML



Income Taxes (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010
Income Taxes [Abstract]
Effective tax rate (in hundredths)	22.50%	24.60%	23.70%	24.60%
Discrete tax charge		$ 0.5		$ 0.5
Estimated reduction of unrecognized tax benefits	0.8		0.8
Tax-related interest expense			0.1	0.1
Accrued interest	$ 0.5		$ 0.5		$ 0.4

XML



CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Millions	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash flows from operating activities:
Net income	$ 39.7	$ 41.6
Depreciation	36.5	33.2
Amortization	2.3	2.2
Other non-cash items, net	3.4	1.0
Changes in assets and liabilities	(32.7)	(34.9)
Net cash provided by operating activities	49.2	43.1
Cash flows from investing activities:
Capital expenditures	(37.8)	(32.6)
Acquisition of business, net of cash acquired	0	(1.3)
Acquisition of patents and other long-term assets	(0.4)	0
Purchases of investments, net	(14.6)	(2.8)
Other, net	0.6	0.1
Net cash used in investing activities	(52.2)	(36.6)
Cash flows from financing activities:
Borrowings under revolving credit agreements, net	6.0	21.9
Repayment of former credit facility	0	(26.6)
Debt issuance costs	(0.3)	(1.6)
Changes in other debt	(0.5)	(0.5)
Dividend payments	(11.4)	(10.7)
Excess tax benefit from employee stock plans	3.1	2.0
Shares repurchased for employee tax withholdings	(3.5)	(2.1)
Issuance of common stock from treasury	3.9	2.4
Net cash used in financing activities	(2.7)	(15.2)
Effect of exchange rates on cash	5.9	(6.9)
Net increase (decrease) in cash and cash equivalents	0.2	(15.6)
Cash, including cash equivalents at beginning of period	110.2	83.1
Cash, including cash equivalents at end of period	$ 110.4	$ 67.5

XML



Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2011

Fair Value Measurements [Abstract]

Schedule of assets and liabilities measured at fair value on a recurring basis

The following tables present the assets and liabilities that are measured at fair value on a recurring basis in our balance sheets:

	Balance at		Basis of Fair Value Measurements
	June 30,
($ in millions)	2011		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	15.4	$	15.4	$	-	$	-
Deferred compensation assets		3.6		3.6		-		-
Commodity contracts		1.1		-		1.1		-
	$	20.1	$	19.0	$	1.1	$	-
Liabilities:
Contingent consideration	$	1.7	$	-	$	-	$	1.7
Deferred compensation liabilities		5.3		5.3		-		-
Foreign currency contracts		1.2		-		1.2		-
Interest rate swap contracts		6.8		-		6.8		-
	$	15.0	$	5.3	$	8.0	$	1.7

	Balance at		Basis of Fair Value Measurements
	December 31,
($ in millions)	2010		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	0.6	$	0.6	$	-	$	-
Deferred compensation assets		3.6		3.6		-		-
	$	4.2	$	4.2	$	-	$	-
Liabilities:
Contingent consideration	$	2.3	$	-	$	-	$	2.3
Deferred compensation liabilities		5.4		5.4		-		-
Interest rate swap contracts		6.1		-		6.1		-
	$	13.8	$	5.4	$	6.1	$	2.3

Summary of changes in Level 3 fair value measurements

The following table provides a summary of changes in our Level 3 fair value measurements:

	($ in millions)
Balance, December 31, 2010	$	2.3
Increase in fair value recorded in earnings		0.1
Reduction in fair value recorded in earnings		(0.8	)
Changes in foreign currency exchange rates		0.1
Balance, June 30, 2011	$	1.7

XML



Net Income Per Share (Tables)

6 Months Ended

Jun. 30, 2011

Net income per share

Net income and shares used in basic and diluted net income per share

The following table reconciles net income and shares used in the calculation of basic net income per share to those used for diluted net income per share:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
($ in millions)	2011		2010		2011		2010
Net income, as reported, for basic net income per share	$	20.1	$	21.7	$	39.7	$	41.6
Plus: interest expense on convertible debt, net of tax		1.1		1.1		2.1		2.1
Net income for diluted net income per share	$	21.2	$	22.8	$	41.8	$	43.7

Weighted average common shares outstanding	33.6	33.3	33.5	33.2
Assumed stock options exercised and awards vested, based on the treasury stock method	0.5	0.5	0.5	0.5
Assumed conversion of convertible debt, based on the if-converted method	2.9	2.9	2.9	2.9
Weighted average shares assuming dilution	37.0	36.7	36.9	36.6

XML



Restructuring and Other Items

6 Months Ended

Jun. 30, 2011

Restructuring and Other Items [Abstract]

Restructuring and Other Items

Note 2:  Restructuring and Other Items

Restructuring and other items consisted of:

	Three Months Ended					Six Months Ended
	June 30,					June 30,
($ in millions)	2011			2010		2011			2010
Restructuring and related charges:
Severance and post-employment benefits	$	0.3		$	-	$	1.7		$	0.4
Impairments and asset write-offs		0.4			0.3		0.7			0.4
Other restructuring charges		0.6			0.1		0.8			0.2
Total restructuring and related charges		1.3			0.4		3.2			1.0
Acquisition-related contingencies		(0.7	)		-		(0.7	)		-
Foreign exchange losses and other		0.4			0.8		0.2			1.5
Total restructuring and other items	$	1.0		$	1.2	$	2.7		$	2.5

Restructuring and Related Charges

In December 2010, our Board of Directors approved a restructuring plan designed to reduce our cost structure and improve operating efficiency. The plan involves the 2011 closure of a plant in the U.S., a longer-term reduction in operations at a manufacturing facility in England, and the elimination of certain operational and administrative positions at various other locations. We expect to incur total restructuring and related charges of approximately $22.0 million to $23.0 million through the end of 2012, which consists of $15.0 million to $16.0 million in cash expenditures for severance and costs associated with the plant closure and fixed asset relocation, and approximately $7.0 million in non-cash asset impairment and disposal charges. We have incurred $14.5 million of restructuring and related charges, as part of this plan, in December of 2010 and $3.2 million during the six months ended June 30, 2011. We currently expect to incur total charges of approximately $5.0 million during the full year 2011, and the remainder during 2012.

During the first six months of 2010, we incurred $1.0 million in restructuring and related charges in connection with the 2009 restructuring program.

The following table presents activity related to our restructuring obligations during the six months ended June 30, 2011:

($ in millions)	Severance and benefits			Other Costs			Total
Balance, December 31, 2010	$	10.2		$	-		$	10.2
Charges		1.7			0.8			2.5
Cash payments		(2.3	)		(0.8	)		(3.1	)
Foreign currency translation adjustments		(0.1	)		-			(0.1	)
Balance, June 30, 2011	$	9.5		$	-		$	9.5

Other Items

During the second quarter of 2011, we reduced the contingent consideration liability related to the July 2009 acquisition of the erisT safety syringe system by $0.8 million. The liability as of June 30, 2011 is now zero, which reflects our assessment that none of the contractual operating targets will be achieved over the earnout period ending in 2014. Partially offsetting this reduction was an increase in contingent consideration expense related to our 2010 acquisition of La Model, Ltd.

XML



Benefit Plans

6 Months Ended

Jun. 30, 2011

Benefit Plans [Abstract]

Benefit Plans

Note 11:  Benefit Plans

The components of net periodic benefit cost for the three months ended June 30 were as follows ($ in millions):

	Pension benefits						Other retirement benefits				Total
	2011			2010			2011		2010		2011			2010
Service cost	$	2.4		$	2.2		$	0.3	$	0.3	$	2.7		$	2.5
Interest cost		4.4			3.8			0.2		0.2		4.6			4.0
Expected return on assets		(4.5	)		(3.5	)		-		-		(4.5	)		(3.5	)
Amortization of prior service credit		(0.4	)		(0.3	)		-		-		(0.4	)		(0.3	)
Recognized actuarial losses		1.4			1.3			-		-		1.4			1.3
Net periodic benefit cost	$	3.3		$	3.5		$	0.5	$	0.5	$	3.8		$	4.0

	Pension benefits				Other retirement benefits				Total
	2011		2010		2011		2010		2011		2010
U.S. plans	$	2.7	$	3.1	$	0.5	$	0.5	$	3.2	$	3.6
International plans		0.6		0.4		-		-		0.6		0.4
Net periodic benefit cost	$	3.3	$	3.5	$	0.5	$	0.5	$	3.8	$	4.0

The components of net periodic benefit cost for the six months ended June 30 were as follows ($ in millions):

	Pension benefits						Other retirement benefits				Total
	2011			2010			2011		2010		2011			2010
Service cost	$	4.8		$	4.5		$	0.6	$	0.5	$	5.4		$	5.0
Interest cost		7.9			7.6			0.5		0.5		8.4			8.1
Expected return on assets		(7.9	)		(7.0	)		-		-		(7.9	)		(7.0	)
Amortization of transition obligation		0.1			-			-		-		0.1			-
Amortization of prior service credit		(0.8	)		(0.6	)		-		-		(0.8	)		(0.6	)
Recognized actuarial losses		2.8			2.6			-		-		2.8			2.6
Net periodic benefit cost	$	6.9		$	7.1		$	1.1	$	1.0	$	8.0		$	8.1

	Pension benefits				Other retirement benefits				Total
	2011		2010		2011		2010		2011		2010
U.S. plans	$	5.4	$	6.2	$	1.1	$	1.0	$	6.5	$	7.2
International plans		1.5		0.9		-		-		1.5		0.9
Net periodic benefit cost	$	6.9	$	7.1	$	1.1	$	1.0	$	8.0	$	8.1

XML



Net Income Per Share (Details) (USD $) In Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Net income per share
Net income, as reported, for basic net income per share	$ 20.1	$ 21.7	$ 39.7	$ 41.6
Plus: interest expense on convertible debt, net of tax	1.1	1.1	2.1	2.1
Net income for diluted net income per share	$ 21.2	$ 22.8	$ 41.8	$ 43.7
Weighted average common shares outstanding	33.6	33.3	33.5	33.2
Assumed stock options exercised and awards vested, based on the treasury stock method	0.5	0.5	0.5	0.5
Assumed conversion of convertible debt, based on the if-converted method	2.9	2.9	2.9	2.9
Weighted average shares assuming dilution	37.0	36.7	36.9	36.6
Antidilutive options excluded from computation of diluted net income per share	1.0	1.3	1.2	1.0

XML



Restructuring and Other Items (Tables)

6 Months Ended

Jun. 30, 2011

Restructuring and Other Items [Abstract]

Schedule of restructuring and other items

Restructuring and other items consisted of:

	Three Months Ended					Six Months Ended
	June 30,					June 30,
($ in millions)	2011			2010		2011			2010
Restructuring and related charges:
Severance and post-employment benefits	$	0.3		$	-	$	1.7		$	0.4
Impairments and asset write-offs		0.4			0.3		0.7			0.4
Other restructuring charges		0.6			0.1		0.8			0.2
Total restructuring and related charges		1.3			0.4		3.2			1.0
Acquisition-related contingencies		(0.7	)		-		(0.7	)		-
Foreign exchange losses and other		0.4			0.8		0.2			1.5
Total restructuring and other items	$	1.0		$	1.2	$	2.7		$	2.5

Rollforward of restructuring obligations

The following table presents activity related to our restructuring obligations during the six months ended June 30, 2011:

($ in millions)	Severance and benefits			Other Costs			Total
Balance, December 31, 2010	$	10.2		$	-		$	10.2
Charges		1.7			0.8			2.5
Cash payments		(2.3	)		(0.8	)		(3.1	)
Foreign currency translation adjustments		(0.1	)		-			(0.1	)
Balance, June 30, 2011	$	9.5		$	-		$	9.5

XML



CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $) In Millions, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Consolidated Statement of Income [Abstract]
Net sales	$ 307.9	$ 281.8	$ 603.3	$ 556.5
Cost of goods and services sold	223.3	198.6	430.7	391.1
Gross profit	84.6	83.2	172.6	165.4
Research and development	7.3	5.7	14.2	11.1
Selling, general and administrative expenses	48.5	45.8	99.2	92.4
Restructuring and other items (Note 2)	1.0	1.2	2.7	2.5
Operating profit	27.8	30.5	56.5	59.4
Interest expense	4.6	3.9	9.3	7.9
Interest income	(0.3)	(0.1)	(0.5)	(0.2)
Income before income taxes	23.5	26.7	47.7	51.7
Income tax expense	5.3	6.6	11.3	12.7
Equity in net income of affiliated companies	1.9	1.6	3.3	2.6
Net income	$ 20.1	$ 21.7	$ 39.7	$ 41.6
Net income per share
Basic	$ 0.60	$ 0.65	$ 1.18	$ 1.25
Diluted	$ 0.57	$ 0.62	$ 1.13	$ 1.19
Weighted average shares outstanding:
Basic	33.6	33.3	33.5	33.2
Diluted	37.0	36.7	36.9	36.6
Dividends declared per share	$ 0.17	$ 0.16	$ 0.34	$ 0.32

XML



Stock-Based Compensation (Details) (USD $)			6 Months Ended
	Jun. 30, 2011	May 03, 2011	Jun. 30, 2011 Stock Options [Member]	Jun. 30, 2011 Performance-Vesting Share (PVS) Awards [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Shares available for issuance under the 2011 Plan (in shares)	4,735,429	4,800,000
Granted (in shares)			471,468
Weighted average exercise price (per share)			$ 40.85
Vesting period (in years)			Four	Three
Expiration period (in years)			Ten
Weighted average grant date fair value (per share)			$ 8.76
Assumptions used in Black-Scholes model
Risk-free interest rate			2.16%
Expected life (in years)			5.5
Stock volatility			24.30%
Dividend yield			1.70%
Number of shares of common stock per PVS award (in shares)				1
PVS payout, Minimum				0.00%
PVS payout, Maximum				200.00%
Granted, PVS awards (in shares)				101,099
Weighted average grant-date fair value (per share)				$ 40.85
Reduction in number of shares available for issuance, stock option and stock appreciation rights				one share for each award granted
Reduction in number of shares available for issuance, all other awards				2.35 times the number of shares awarded

XML



Benefit Plans (Details) (USD $) In Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Benefit Plans Disclosure [Line Items]
Service cost	$ 2.7	$ 2.5	$ 5.4	$ 5.0
Interest cost	4.6	4.0	8.4	8.1
Expected return on assets	4.5	3.5	7.9	7.0
Amortization of transition obligation			0.1	0
Amortization of prior service credit	(0.4)	(0.3)	(0.8)	(0.6)
Recognized actuarial losses	1.4	1.3	2.8	2.6
Net periodic benefit cost	3.8	4.0	8.0	8.1
Pension Benefits [Member]
Benefit Plans Disclosure [Line Items]
Service cost	2.4	2.2	4.8	4.5
Interest cost	4.4	3.8	7.9	7.6
Expected return on assets	4.5	3.5	7.9	7.0
Amortization of transition obligation			0.1	0
Amortization of prior service credit	(0.4)	(0.3)	(0.8)	(0.6)
Recognized actuarial losses	1.4	1.3	2.8	2.6
Net periodic benefit cost	3.3	3.5	6.9	7.1
Other Retirement Benefits [Member]
Benefit Plans Disclosure [Line Items]
Service cost	0.3	0.3	0.6	0.5
Interest cost	0.2	0.2	0.5	0.5
Expected return on assets	0	0	0	0
Amortization of transition obligation			0	0
Amortization of prior service credit	0	0	0	0
Recognized actuarial losses	0	0	0	0
Net periodic benefit cost	0.5	0.5	1.1	1.0
International Other Retirement Benefit Plans [Member]
Benefit Plans Disclosure [Line Items]
Net periodic benefit cost	0	0	0	0
U.S. Other Retirement Benefit Plans [Member]
Benefit Plans Disclosure [Line Items]
Net periodic benefit cost	0.5	0.5	1.1	1.0
International Pension Benefit Plans [Member]
Benefit Plans Disclosure [Line Items]
Net periodic benefit cost	0.6	0.4	1.5	0.9
U.S. Pension Benefit Plans [Member]
Benefit Plans Disclosure [Line Items]
Net periodic benefit cost	2.7	3.1	5.4	6.2
U.S. Plans [Member]
Benefit Plans Disclosure [Line Items]
Net periodic benefit cost	3.2	3.6	6.5	7.2
International Plans [Member]
Benefit Plans Disclosure [Line Items]
Net periodic benefit cost	$ 0.6	$ 0.4	$ 1.5	$ 0.9